MannKind
MNKD | NASDAQ
$3.96
-$0.17 (-4.12%)
At close: Nov 16, 2026, 4:00 PM ET
$3.96
$0.00 (0.00%)
After-hours:
Nov 16, 2026, 7:30 PM ET
MannKind Company Profile
Company profile explainedCompany Profile
MannKind Corporation operates as a biopharmaceutical firm, primarily focused on innovating and bringing to market respiratory-delivered treatments. Its efforts are directed towards tackling endocrine system disorders and rare lung conditions within the U.S. market. The company's key product is Afrezza, an inhaled insulin designed to improve glycemic control for adults managing diabetes. MannKind also actively markets Thyquidity, promoting it to adult and pediatric endocrinologists and other healthcare professionals for the treatment of hypothyroidism. In terms of collaborations, MannKind holds a strategic licensing and partnership agreement with United Therapeutics Corporation. Furthermore, it is collaborating with NRx Pharmaceuticals to develop a dry powder formulation of ZYESAMI (aviptadil), which is a synthetic variant of human vasoactive intestinal peptide intended to shield cells from inflammatory processes. Established in 1991, MannKind Corporation's corporate offices are located in Westlake Village, California.
Key Executives
| Name | Position |
|---|---|
| Michael E. Castagna | Chief Executive Officer & Director |
| Christopher Prentiss | Chief Financial Officer |
| Ajay Ahuja | Executive VP & Chief Medical Officer |
| David Thomson | Executive Vice President, General Counsel & Secretary |
| Dominic Marasco | President of Endocrine Business Unit |
| Sanjay Singh | Executive Vice President of Technical Operations |
| Stuart A. Tross | Chief People & Workplace Officer |
| Wassim Fares | Senior VP and Therapeutic Area Head of Respiratory & (interim) Cariorenal |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Sep 28, 2026 | 4 | Filing |
| Sep 14, 2026 | 4 | Filing |
| Aug 21, 2026 | 8-K | Current Report |
| Aug 21, 2026 | 424B7 | Filing |
| Aug 14, 2026 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Aug 10, 2026 | 4 | Filing |
| Aug 05, 2026 | 10-Q | Quarterly Report |
| Aug 05, 2026 | 8-K | Current Report |
| Jul 31, 2026 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Jul 24, 2026 | 8-K | Current Report |
MannKind
| Country | United States |
| IPO Date | Jul 28, 2004 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 592 |
| CEO | Michael E. Castagna |
Contact Details
1 Casper Street Danbury,
California 06810 United States
Stock Details
| Ticker Symbol | MNKD |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000899460 |
| CUSIP Number | 56400P706 |
| ISIN Number | US56400P7069 |
| SIC Code | 2834 |
Recent News
- 5 days ago / seekingalpha.comMannKind's ReadyFlow Launch Keeps The Bull Case Alive
- 11 days ago / seekingalpha.comMannKind Corporation (MNKD) Q3 2026 Earnings Call Transcript
- 11 days ago / marketbeat.comMannKind Q3 Earnings Call Highlights
- 11 days ago / zacks.comCompared to Estimates, MannKind (MNKD) Q3 Earnings: A Look at Key Metrics
- 11 days ago / zacks.comMannKind (MNKD) Reports Q3 Loss, Misses Revenue Estimates
- 18 days ago / globenewswire.comMannKind to Report Third Quarter Financial Results and Host Conference Call on November 5, 2026
- 1 month ago / globenewswire.comMannKind Data at HFSA 2026 Highlights New Evidence Supporting Furoscix ReadyFlow™ for the Outpatient Management of Edema in Heart Failure (HF) and Chronic Kidney Disease (CKD)
- 2 months ago / marketbeat.comMannKind Sees Early ReadyFlow Demand as Pediatric Afrezza Launch Gains Momentum
- 2 months ago / globenewswire.comMannKind and Rose Pharma Inc Enter Licensing and Collaboration Agreement to Develop an Inhaled Rapid-Acting, Short-Duration GLP-1 for Weight Management
- 3 months ago / globenewswire.comMannKind to Present at Upcoming Investor Conferences
Add to Watchlist
Select watchlists to add or remove MNKD